Companies › Bayer
22 active drug programs in 132 registered trials: 64 Phase 2, 32 Phase 3, 24 Phase 1, 12 Phase 4; Oncology, Cardiovascular, Other, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Radium-223 dichloride (Xofigo, BAY88-8223) Radium-223 is a radioactive alpha emitter that is taken up by bones and delivers localized | – | Phase 4 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Nov 2026 |
| Darolutamide Androgen Receptor antagonist | AR | Phase 4 | Non-metastatic Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Cancer; Cancer; High-risk Localized Prostate Cancer … | Jul 2027 |
| Elinzanetant (BAY3427080) Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist | TACR1, TACR3 | Phase 3 | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women; Menopause-related Hot Flashes | Feb 2027 |
| Finerenone (BAY94) Mineralocorticoid receptor antagonist | NR3C2 | Phase 3 | Chronic Kidney Disease; Left Ventricular Systolic Dysfunction; Primary Membranous Nephropathy; Heart Failure … | Apr 2027 |
| BAY 2927088 (Sevabertinib) MATE1 and MATE2-K transporter inhibitor | ERBB2, SLC47A1, SLC47A2 | Phase 3 | Advanced Non-small Cell Lung Cancer, HER2 Mutation; Advanced Solid Tumors; Healthy Participants | Oct 2027 |
| Riociguat Soluble guanylate cyclase positive allosteric modulator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 3 | Hypertension, Pulmonary; Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Arterial Hypertension | May 2028 |
| Aficamten (BAY3723113, CK-3773274) Cardiac myosin inhibitor | MYH7 | Phase 3 | Obstructive Hypertrophic Cardiomyopathy | May 2028 |
| BAY 3401016 Semaphorin 3A (Sema3A) antagonist monoclonal antibody | SEMA3A | Phase 2 | Alport Syndrome | Nov 2027 |
| Regorafenib (BAY73) Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor | ABL1, RAF1, KIT, FGFR1, MAPK11 | Phase 2 | Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic … | Apr 2028 |
| BAY 3670549 | – | Phase 2 | Atrial Fibrillation | May 2030 |
| BAY3389934 Factor IIa (thrombin) and Factor Xa inhibitor | F2, F10 | Phase 1 | Sepsis; Drug-drug Interaction | Dec 2026 |
| BAY2965501 T-cell co-stimulatory agonist; blocks an enzyme in T-cells to activate them | – | Phase 1 | Advanced Solid Tumors | Apr 2027 |
| BAY3498264 SOS1 inhibitor | SOS1 | Phase 1 | Advanced Solid Tumors Harboring KRAS G12C Mutation | Apr 2027 |
| BAY3375968 (Lanerkitug) Anti-CCR8 antibody | CCR8 | Phase 1 | Advanced Solid Tumors | Apr 2027 |
| Actinium-225-macropa-pelgifatamab (BAY3546828) Alpha-emitting radiopharmaceutical targeting GPRC5D; actinium-225 chelated by macropa conj | GPRC5D | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Jun 2027 |
| 225Ac-PSMA-Trillium (BAY3563254) PSMA-targeting alpha-emitting radioligand (actinium-225) | PSMA | Phase 1 | Advanced Metastatic Castration-resistant Prostate Cancer | Nov 2028 |
| BAY2927088 (sevabertinib) Tyrosine kinase inhibitor targeting mutated EGFR and HER2 | EGFR, HER2 | Phase 1 | Advanced Non-small Cell Lung Cancer | Dec 2028 |
| BAY 3713372 PRMT5 inhibitor | PRMT5 | Phase 1 | MTAP-deleted Solid Tumors | Jun 2029 |
| BAY 3771249 KRAS G12D inhibitor | KRAS | Phase 1 | Advanced/Metastatic Colorectal Adenocarcinoma | Jul 2029 |
| BAY 3547926 anti-GPC3 antibody-drug conjugate with actinium-225 alpha emitter | GPC3 | Phase 1 | Hepatocellular Carcinoma | Jul 2029 |
| Larotrectinib (BAY2757556) Neurotrophic tyrosine kinase receptor inhibitor | NTRK1, NTRK2, NTRK3 | Phase 1 | Solid Tumors Harboring NTRK Fusion; Advanced Malignant Solid Neoplasm; Advanced Lymphoma; Central Nervous System Neoplasm … | – |
| Nurandociguat (BAY3283142) new tablet solute carrier family 22 member 8 (SLC22A8) activator | – | Phase 1 | Chronic Kidney Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02637687 | Larotrectinib (BAY2757556) | Phase 1 | Solid Tumors Harboring NTRK Fusion | Oncology | Jul 2024 |
| NCT03829462 | Regorafenib (BAY73) | Phase 3 | Metastatic Colorectal Cancer (mCRC) | Oncology | Sep 2024 |
| NCT03213704 | Larotrectinib (BAY2757556) | Phase 2 | Advanced Malignant Solid Neoplasm | Oncology | Sep 2024 |
| NCT03385655 | Darolutamide | Phase 2 | Prostate Cancer | Oncology | Oct 2024 |
| NCT04803877 | Regorafenib (BAY73) | Phase 2 | Osteosarcoma | Oncology | Nov 2025 |
| NCT03899428 | Regorafenib (BAY73) | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2025 |
| NCT04062565 | Riociguat | Phase 3 | Pulmonary Arterial Hypertension | Cardiovascular | Dec 2025 |
| NCT04319783 | Darolutamide | Phase 2 | Advanced Prostate Carcinoma | Oncology | Jun 2026 |
| NCT06631521 | Darolutamide | Phase 1 | Prostate CA | Oncology | Jun 2026 |
| NCT05057052 | Regorafenib (BAY73) | Phase 2 | Liver Metastases | Oncology | Sep 2026 |
| NCT07753252 | BAY 2927088 (Sevabertinib) | Phase 1 | Healthy Participants | Other | Oct 2026 |
| NCT07722585 | Nurandociguat (BAY3283142) new tablet | Phase 1 | Chronic Kidney Disease | Genitourinary | Oct 2026 |
| NCT06573411 | Finerenone (BAY94) | Phase 4 | Primary Membranous Nephropathy | Genitourinary | Oct 2026 |
| NCT07351864 | Finerenone (BAY94) | Phase 4 | Heart Failure | Cardiovascular | Oct 2026 |
| NCT05050084 | Darolutamide | Phase 3 | Prostate Adenocarcinoma | Oncology | Nov 2026 |
| NCT06173362 | Darolutamide | Phase 2 | Advanced Prostate Adenocarcinoma | Oncology | Nov 2026 |
| NCT05622136 | Regorafenib (BAY73) | Phase 2 | Liver Cancer | Oncology | Nov 2026 |
| NCT05644379 | Regorafenib (BAY73) | Phase 1 | Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy | Oncology | Nov 2026 |
| NCT04597125 | Radium-223 dichloride (Xofigo, BAY88-8223) | Phase 4 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Oncology | Nov 2026 |
| NCT05669664 | Darolutamide | Phase 2 | Locally Advanced Salivary Gland Carcinoma | Oncology | Nov 2026 |
| NCT05672316 | Regorafenib (BAY73) | Phase 1 | Advanced Colorectal Adenocarcinoma | Oncology | Dec 2026 |
| NCT06627530 | Darolutamide | Phase 4 | Prostate Cancer | Oncology | Dec 2026 |
| NCT05676203 | Darolutamide | Phase 3 | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Oncology | Dec 2026 |
| NCT05346848 | Darolutamide | Phase 2 | Prostate Cancer | Oncology | Dec 2026 |
| NCT05370807 | Regorafenib (BAY73) | Phase 2 | Melanoma Stage III | Oncology | Dec 2026 |
| NCT05370807 | Regorafenib (BAY73) | Phase 2 | Melanoma Stage III | Oncology | Dec 2026 |
| NCT04781192 | Regorafenib (BAY73) | Phase 1 | Advanced Biliary Tract Cancer | Oncology | Dec 2026 |
| NCT06854640 | BAY3389934 | Phase 1 | Sepsis | Hematology | Dec 2026 |
| NCT05917431 | Regorafenib (BAY73) | Phase 2 | Unresectable Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT07026539 | Finerenone (BAY94) | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Genitourinary | Dec 2026 |
| NCT06727409 | Finerenone (BAY94) | Phase 4 | Patients With Type 2 Diabetes | Metabolic and endocrine | Dec 2026 |
| NCT07501351 | Regorafenib (BAY73) | Phase 2 | Hepatocellulcar Carcinoma | Oncology | Dec 2026 |
| NCT06099821 | Regorafenib (BAY73) | Phase 2 | Digestive System Cancers | Oncology | Dec 2026 |
| NCT04503694 | Regorafenib (BAY73) | Phase 2 | Rectal Cancer Stage II | Oncology | Dec 2026 |
| NCT05366816 | Regorafenib (BAY73) | Phase 2 | Gastrointestinal Stromal Tumors | Oncology | Dec 2026 |
| NCT06390852 | Larotrectinib (BAY2757556) | Phase 2 | Advanced Lymphoma | Oncology | Dec 2026 |
| NCT06363006 | Regorafenib (BAY73) | Phase 1 | Hepatocellular Carcinoma | Oncology | Jan 2027 |
| NCT06715280 | Riociguat | Phase 4 | Chronic Thromboembolic Pulmonary Hypertension | Cardiovascular | Jan 2027 |
| NCT05116475 | Darolutamide | Phase 3 | Prostate Cancer | Oncology | Feb 2027 |
| NCT05113368 | Regorafenib (BAY73) | Phase 2 | Ovarian Cancer | Oncology | Feb 2027 |
| NCT04757363 | Regorafenib (BAY73) | Phase 2 | Esophagogastric Cancer | Oncology | Feb 2027 |
| NCT07762287 | Elinzanetant (BAY3427080) | Phase 1 | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women | Genitourinary | Feb 2027 |
| NCT07652723 | BAY3389934 | Phase 1 | Drug-drug Interaction | Other | Mar 2027 |
| NCT06059664 | Finerenone (BAY94) | Phase 2 | Kidney Transplant; Complications | Cardiovascular | Mar 2027 |
| NCT05794971 | Regorafenib (BAY73) | Phase 3 | Colorectal Cancer Liver Metastases | Oncology | Mar 2027 |
| NCT06280105 | Regorafenib (BAY73) | Phase 2 | Hepatocellular Carcinoma | Oncology | Mar 2027 |
| NCT05196035 | Finerenone (BAY94) | Phase 3 | Chronic Kidney Disease | Genitourinary | Apr 2027 |
| NCT05614102 | BAY2965501 | Phase 1 | Advanced Solid Tumors | Oncology | Apr 2027 |
| NCT07213570 | Regorafenib (BAY73) | Phase 2 | Colorectal Cancer Metastatic | Oncology | Apr 2027 |
| NCT05830084 | Regorafenib (BAY73) | Phase 1 | Ewing Sarcoma | Oncology | Apr 2027 |
| NCT06659341 | BAY3498264 | Phase 1 | Advanced Solid Tumors Harboring KRAS G12C Mutation | Oncology | Apr 2027 |
| NCT06930118 | Regorafenib (BAY73) | Phase 2 | Advanced Colorectal Cancer in the Third-line Treatment and Beyond | Oncology | Apr 2027 |
| NCT05537740 | BAY3375968 (Lanerkitug) | Phase 1 | Advanced Solid Tumors | Oncology | Apr 2027 |
| NCT07071961 | Regorafenib (BAY73) | Phase 2 | Colorectal Cancer | Oncology | May 2027 |
| NCT05762536 | Darolutamide | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | May 2027 |
| NCT07040228 | Regorafenib (BAY73) | Phase 1 | Pancreatic Cancer Metastatic | Oncology | May 2027 |
| NCT07559864 | Regorafenib (BAY73) | Phase 2 | GIST - Gastrointestinal Stromal Tumor | Oncology | Jun 2027 |
| NCT06052306 | Actinium-225-macropa-pelgifatamab (BAY3546828) | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Jun 2027 |
| NCT07617272 | Darolutamide | Phase 2 | Prostate Cancer (Adenocarcinoma) | Oncology | Jun 2027 |
| NCT03834961 | Larotrectinib (BAY2757556) | Phase 2 | Central Nervous System Neoplasm | Oncology | Jul 2027 |
The 60 nearest readouts of 132 trials; the rest in the app.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.